Outstanding Recoveries
- Home
- Outstanding Recoveries
Verdicts & Settlements
Since Milberg’s founding in 1965, the firm has recovered more than $50 billion for our clients while prompting meaningful changes in corporate governance.
Filter By
Select Practice Area
-
See More$110 Million Settlement – CVS Corp. Securities Litigation
In re CVS Corp. Securities Litigation, No. 01-11464 (D. Mass.)Milberg served as Co-Lead Counsel in this securities class action alleging that defendants issued false and misleading statements, which artificially inflated the price of CVS stock. In 2005, the court approved a $110 million settlement. -
See More$118+ Million Settlement – Disposable Contact Lens Antitrust Litigation
In re Disposable Contact Lens Antitrust Litigation, 3:15-md-02626 (U.S. District Court for the Middle District of Florida)Milberg represented indirect purchasers in a class action alleging that defendants conspired to maintain artificially high prices for disposable contact lenses through policies that prevented resale of the subject contact lenses below a minimum price. Settlements exceeded $118 million. -
See More$90 Million Settlement – Royal Dutch/Shell Transport ERISA Litigation
In re Royal Dutch/Shell Transport ERISA Litigation, No. 04-1398 (D.N.J.)An ERISA breach of fiduciary duty class action against the Royal Dutch/Shell Oil Group of Companies on behalf of certain of the companies’ U.S. employee investment plan participants. The $90 million settlement included important provisions regarding the monitoring and training of individuals appointed to be ERISA fiduciaries. -
See More$138 Million Settlement – Biovail Corp. Securities Litigation
In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes. -
See More$62 Million Settlement – Comverse Technology, Inc. Derivative Litigation
In re Comverse Technology, Inc. Derivative Litigation, No. 601272/2006 (N.Y. Sup. Ct. N.Y. Cnty.)As Co-Lead Counsel, Milberg negotiated a $62 settlement which was approved by the court in 2010. The settlement also resulted in significant corporate governance reforms, including the replacement of various directors and officers; the amendment of the company’s bylaws to permit certain shareholders to propose in the company’s proxy materials nominees for election as directors; and the requirement that all equity grants be approved by both the compensation committee and a majority of the non-employee directors.
